A team of researchers developed a tool that integrates all epidemiological indicators and compares the evolution between countries.
The HUB-ICO-IDIBELL Biobank responds to the pandemic and creates a collection of COVID-19 samples for research
THE ICO-HUB-IDIBELL Biobank has created a collection of sera, plasma, DNA and RNA samples from patients confirmed by SARS-CoV-2 to make available to the scientific community
The projects focus on the study of the virus biology, the immunity that generates and clinical manifestations of the disease.
IDIBELL has participated in a study published in Nature Genetics that describes alterations in the neurons of the intestine and oligodendrocytes in Parkinson’s disease
The sustainable development project ‘Junto@s por el clima’ (‘Together for the climate’) designed by the students has been awarded with 5,000 euros, that they have decided to give to IDIBELL.
IDIBELL has participated in a study that describes that the ability to produce proteins defines tumor stem cells
Protein production is what defines tumor stem cells, making this function an ideal therapeutic target.
DNA repair mechanisms in some ovarian cancer tumors are highly dependent on oxidative metabolism. Process that can be inhibited with drugs like Metformin.
Fake news and disinformation campaigns are beginning to circulate in certain social sectors, which may lead to an increase in the number of people against vaccination. A boycott of mass prophylaxis against Covid-19 whenever it becomes available would mean thousands of deaths.
When Covid-19 pandemic had just started, the Clinic Hematology group published a series of recommendations for the management of cancer patients. Now, have the recommended measures been implemented? Have they been effective? We have discussed this with those responsible of the study.
A study with IDIBELL participation determines the optimal number of chemotherapy cycles to treat glioblastoma
The clinical trial, published in the journal ‘Neuro Oncology’, shows that increasing the number of cycles of temozolomide in patients with this type of tumor does not provide additional benefits and increases the toxicity of the treatment.